Clinical trial Archives

News and Trends 3 Jan 2023

Legend Biotech new drug application approved in China

Legend Biotech Corporation has announced that China’s National Medical Products Administration (NMPA) has formally accepted its new drug application (NDA) for ciltacabtagene autoleucel (cilta-cel). This submission is based on data from the confirmatory phase 2 clinical study CARTIFAN-1, conducted in China, which evaluated the efficacy and safety of cilta-cel in adult patients with relapsed or […]

January 3, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 3 Jan 2023

Newron announces interim results from treatment-resistant schizophrenia trial

Newron Pharmaceuticals S.p.A. has announced what it says are “very compelling new results” from the first 100 enrolled patients to have reached the six-month timepoint in its international study of evenamide as an add-on to an antipsychotic (excluding clozapine) in patients with moderate to severe treatment-resistant schizophrenia (TRS), who were not responding to their current […]

January 3, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 3 Jan 2023

Sensorion announces first patient enrolled in cisplatin-induced ototoxicity trial

Sensorion has announced that the first patient has been enrolled in its phase 2a proof of concept clinical trial of SENS-401 (Arazasetron) in patients suffering from cisplatin-induced ototoxicity. Cisplatin and other platinum-based compounds are essential chemotherapeutic agents for many cancers. A serious side effect of these therapies is ototoxicity, or permanent and irreversible hearing loss, […]

January 3, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 22 Dec 2022

First CAR-T technology trial for patients with T-cell leukemia subtype authorized

The Spanish Agency of Medicines and Medical Products (AEMPS) has approved the CARxALL clinical trial led by the company OneChain Immunotherapeutics (OCI). It will be the world’s first trial with CAR-T technology for patients with a subtype of T-cell leukemia. The CARxALL trial will evaluate, for the first time, the CAR-T CD1a (OC-1) therapy. This […]

December 22, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 22 Dec 2022

Positive Dupixent eosinophilic esophagitis phase 3 results

The New England Journal of Medicine has published results from a positive phase 3 trial showing adults and adolescents treated with Dupixent (dupilumab) 300 mg weekly experienced significant improvements in signs and symptoms of eosinophilic esophagitis (EoE), which were sustained for up to one year. EoE is a chronic, progressive inflammatory disease that damages the […]

December 22, 2022 - 4 minutesmins - By Jim Cornall

Mauritius EDB Economic Development Board

News and Trends 21 Dec 2022

Watch: Mauritius – clinical trials and emerging biotech hub

The Economic Development Board (EDB) in Mauritius commenced its operations as a statutory body in 2018 following the merger between the Board of Investment, Enterprise Mauritius and the Financial Services Promotion Agency. The overarching objective of the EDB is to ensure greater coherence and effectiveness in implementing policies and draw the vision for the economic […]

December 21, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 21 Dec 2022

Pfizer diabetes and obesity study triggers Sosei Heptares windfall

Sosei Group Corporation has been notified by Pfizer that the first subject in a phase 2 clinical trial has been dosed with Pfizer’s candidate PF-07081532. This triggers a $10 million payment to Sosei Heptares. PF-07081532 is a once-daily, next-generation oral small molecule GLP-1 receptor agonist in development for the treatment of type 2 diabetes and obesity. […]

December 21, 2022 - 3 minutesmins - By Jim Cornall

COPD lung disease chronic obstructive pulmonary disease

News and Trends 20 Dec 2022

Verona Pharma drug meets COPD phase 3 trial endpoints

Verona Pharma plc has announced positive results of its phase 3 ENHANCE-1 trial evaluating nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The ENHANCE-1 trial successfully met its primary and key secondary endpoints demonstrating significant improvements in lung function, symptoms and quality of life measures. In addition, ensifentrine substantially reduced the […]

December 20, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 19 Dec 2022

UroGen completes bladder cancer phase 3 trial enrollment

UroGen Pharma Ltd. says its phase 3 ENVISION study of investigational agent UGN-102 (mitomycin) for intravesical solution in development for the treatment of LG-IR-NMIBC is fully enrolled. The study targeted enrollment of 220 patients across 90 sites and, assuming positive findings, UroGen anticipates submitting a New Drug Application (NDA) for UGN-102 in 2024. “Completing enrollment […]

December 19, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 19 Dec 2022

SoftOx receives chronic wound study report

Norwegian company SoftOx Solutions AS says it has received the final report and analysis of its phase 1 study evaluating the safety and tolerability of SoftOx Biofilm Eradicator (SBE-01). SBE-01 is SoftOx’s antimicrobial solution for the treatment of chronic wounds. The study is a first-in-human investigation of the safety, tolerability, and antimicrobial efficacy of single […]

December 19, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 16 Dec 2022

Astellas gastric cancer drug meets phase 3 primary endpoint

Astellas Pharma Inc. has announced positive topline results from the phase 3 GLOW clinical trial evaluating the efficacy and safety of zolbetuximab in combination with CAPOX (a combination chemotherapy regimen that includes capecitabine and oxaliplatin). Zolbetuximab is an investigational first-in-class claudin-18.2 (CLDN18.2) targeted monoclonal antibody, for the first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally […]

December 16, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 14 Dec 2022

NMD Pharma cleared for spinal muscular atrophy trial

NMD Pharma A/S has received clearance for its investigational new drug (IND) application from the US Food and Drug Administration (FDA) to advance NMD670 into a phase II clinical study in patients of spinal muscular atrophy (SMA) type 3. NMD Pharma is a Danish clinical stage biotech company developing first-in-class, small molecule ClC-1 inhibitors for […]

December 14, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Clinical trial

Legend Biotech new drug application approved in China

Newron announces interim results from treatment-resistant schizophrenia trial

Sensorion announces first patient enrolled in cisplatin-induced ototoxicity trial

First CAR-T technology trial for patients with T-cell leukemia subtype authorized

Positive Dupixent eosinophilic esophagitis phase 3 results

Watch: Mauritius – clinical trials and emerging biotech hub

Pfizer diabetes and obesity study triggers Sosei Heptares windfall

Verona Pharma drug meets COPD phase 3 trial endpoints

UroGen completes bladder cancer phase 3 trial enrollment

SoftOx receives chronic wound study report

Astellas gastric cancer drug meets phase 3 primary endpoint

NMD Pharma cleared for spinal muscular atrophy trial

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!